A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder
Completed
Eli Lilly and Company
Phase 2/Phase 3
The primary purpose of your child's participation in this study is to determine whether
LY2216684 can help pediatric patients with attention-deficit/hyperactivity disorder (ADHD);
and assess the safety of LY2216684 and any side effects that might be associated with it.
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
Terminated
Eli Lilly and Company
Phase 2/Phase 3
The primary purpose of the study is to assess long-term safety and tolerability of
Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).
A Safety Study in Participants With Major Depressive Disorder
Completed
Eli Lilly and Company
Phase 3
The primary objective of this study is to evaluate the long-term safety and tolerability of
LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin
reuptake inhibitor (SSRI) for up to approximately 1 year in participants with major
depressive disorder (MDD) who are partial responders to their SSRI treatment.
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
Completed
Eli Lilly and Company
Phase 3
The primary purpose of this study is to assess whether at least 1 dose of LY2216684 (12
milligrams [mg] or 18 mg once daily) is superior to placebo once daily in the adjunctive
treatment of participants with major depressive disorder (MDD) who were identified as partial
responders to an adequate course of treatment with a selective serotonin reuptake inhibitor
(SSRI) during an 8-week, double-blind, acute adjunctive treatment phase.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
